¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"phase 1 study"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • longitudinal study
    ÃßÀû¿¬±¸
  • molecular genetic study
    ºÐÀÚÀ¯ÀüÇа˻ç
  • neurophysiological study
    ½Å°æ»ý¸®ÇÐÀû°Ë»ç
  • observational study
    °üÂû¿¬±¸
  • pilot study
    ¿¹ºñ¿¬±¸
  • population study
    Àα¸Á¶»ç
  • preclinical study
    ÀÓ»óÀü½ÃÇè, ÀüÀӻ󿬱¸
  • pressure flow study
    ¾Ð·Â¿ä·ù°Ë»ç
  • prospective cohort study
    ÀüÇâÄÚȣƮ¿¬±¸
  • prospective study
    ÀüÇ⿬±¸, °èȹ¿¬±¸
  • real time study
    ½Ç½Ã°£°Ë»ç
  • retrospective cohort study
    ÈÄÇâÄÚȣƮ¿¬±¸
  • retrospective study
    ÈÄÇ⿬±¸
  • study
    1. ¿¬±¸, Á¶»ç 2. °Ë»ç, °Ë»ö
  • study design
    ¿¬±¸¼³°è
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • single blinding study
    ´Ü¼ø¸Í°Ë¹ý
  • urodynamic study
    ¿ä¿ªµ¿Çа˻ç
  • luteal phase endometrial biopsy
    Ȳü±âÀڱ󻸷»ý°Ë
  • phase contrast
    À§»ó´ëÁ¶
  • luteal phase defect
    Ȳü±â°á¼Õ
  • phase difference
    À§»óÂ÷
  • phase-contrast microscope
    À§»óÂ÷Çö¹Ì°æ
  • phase
    »ó, ±â, À§»ó
  • acceleration phase
    ÃËÁø±â, °¡¼Ó±â
  • active phase
    Ȱ¼º±â
  • latent phase
    ÀáÀç±â , Àẹ±â
  • plateau phase
    ÆíÆò±â, °íÁ¶±â
  • relaxation phase
    À̿ϱâ, À̿ϻó
  • resolution phase
    ÇØ¼Ò±â
  • resting phase
    È޽ıâ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • feasibility study
    °¡´É¼º¿¬±¸
  • first pass study
    ÀÏÂ÷Åë°ú°Ë»ç
  • follow-up study
    ÃßÀûÁ¶»ç
  • infection control study
    °¨¿°°ü¸®Á¶»ç
  • intervening study
    °³ÀÔ¿¬±¸
  • longitudinal study
    ÃßÀû¿¬±¸
  • microbiologic study
    ¹Ì»ý¹°Çа˻ç
  • migrant study
    ÀÌÁֹבּ¸
  • mixing study
    È¥ÇÕ°Ë»ç
  • molecular genetic study
    ºÐÀÚÀ¯ÀüÇа˻ç
  • neurophysiological study
    ½Å°æ»ý¸®ÇÐÀû°Ë»ç
  • nonconcurrent study
    ºñµ¿½ÃÀû¿¬±¸
  • observational study
    °üÂû¿¬±¸
  • pilot study
    ¿¹ºñ½ÇÇè
  • population study
    Àα¸Á¶»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acceleration phase
    ÃËÁø±â, °¡¼Ó±â(Ê¥áÜÑ¢).
  • acute phase protein
    ±Þ¼ºº´±â´Ü¹éÁú
  • acute phase reactant
    ±Þ¼º±â ÀÛ¿ë¹°Áú
  • acute phase reaction
    ±Þ¼º±â¹ÝÀÀ(¡­Ñ¢Úãëë)
  • acute phase reactive protein
    ±Þ¼º±â ¹ÝÀÀ¼º ´Ü¹é.
  • acute phase serum
    ±Þ¼ºº´±âÇ÷û
  • acute phase substances
    ±Þ¼º±â ¹°Áú(ÐáàõÑ¢Úªòõ).
  • advanced sleep phase syndrome
    ÀüÁø¼º ¼ö¸éÀ§»ó ÁõÈıº
  • anal-sadistic phase
    Ç×¹®-°¡ÇÐ(½Ã)±â
  • arterial phase
    µ¿¸Æ±â
  • full erection phase
    ¿ÏÀü¹ß±â±â
  • g0 phase
    Á¤Áö±â G0±â
  • g1 phase
    ÇÕ¼ºÀü±â G1±â
  • g2 phase
    ÇÕ¼ºÈıâ G2±â
  • gastric phase
    À§»ó(êÖßÓ) À§»êºÐºñ(êÖߤÝÂÝô)ÀÇ .
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • molecular genetic study
    ºÐÀÚÀ¯ÀüÇÐ<ÀÚ>°Ë»ç
  • nested case control study
  • pilot study
    ¿¹ºñ½ÇÇè.
  • population study
    Àα¸Á¶»ç
  • preclinical study
    ÀüÀÓ»ó½ÃÇè(îñìúßÉãËúÐ).
  • pressure flow study
    ¾Ð·ù·® Á¶»ç
  • pressure-perfusion study
    ¾Ð·Â°ü·ù°Ë»ç
  • prospective study
    °èȹÀû¿¬±¸, ÀüÇâÀû¿¬±¸
  • real time study
    ½Ç½Ã°£ °Ë»ç
  • retrospective study
    ÈÄÇâÀû¿¬±¸
  • single blind study
    ´ÜÀÏ<¼ø>¸Í°Ë¹ý.
  • time study
    ½Ã°£¿¬±¸(¡­æÚϼ).
  • tracer study
    ÃßÀûÀÚ¿¬±¸(õÚîæíºæÚϼ).
  • twin study
    ½Ö»ý¾Æ¿¬±¸(¡­æÚϼ).
  • twin study
    ½Ö»ý¾Æ¿¬?¡­æÚϼ)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Postmenstrual phase
    ¿ù°æÈıâ
    [¿¾ ¿ë¾î] ¿ù°æÈıâ
  • Zygotene phase
    Á¢ÇÕ±â
    [¿¾ ¿ë¾î] Á¢ÇÕ±â
  • Go phase
    Á¤Áö±â [Go±â]
    [¿¾ ¿ë¾î] Á¤Áö±â
  • Proliferative phase
    Áõ½Ä±â
    [¿¾ ¿ë¾î] Áõ½Ä±â
  • Implantational phase
    Âø»ó±â
    [¿¾ ¿ë¾î] Âø»ó±â
  • Preimplantational phase
    Âø»óÀü±â
    [¿¾ ¿ë¾î] Âø»óÀü±â
  • Colostral phase
    ÃÊÀ¯±â
    [¿¾ ¿ë¾î] ÃÊÀ¯±â
  • Placental phase
    Źݱâ
    [¿¾ ¿ë¾î] Źݱâ
  • Involutional phase
    ÅðÈ­±â
    [¿¾ ¿ë¾î] ÅðÈ­±â
  • Proleptotene phase
    Dz¼¶À¯±â
    [¿¾ ¿ë¾î] Àü¼¼»ç±â
  • S phase
    ÇÕ¼º±â [S±â]
    [¿¾ ¿ë¾î] ÇÕ¼º±â
  • G1 phase
    ÇÕ¼ºÀü±â [G1±â]
    [¿¾ ¿ë¾î] ÀÏÂ÷ÈÞÁö±â
  • G2 phase
    ÇÕ¼ºÈıâ [G2±â]
    [¿¾ ¿ë¾î] ÀÌÂ÷ÈÞÁö±â
  • Ischemic phase
    ÇãÇ÷±â
    [¿¾ ¿ë¾î] ºóÇ÷±â
  • Luteal phase
    Ȳ(»ö)ü±â
    [¿¾ ¿ë¾î] Ȳü±â
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • negative phase
    °¨¼Ò±â(Êõá´Ñ¢)
  • normal-phase chromatgoraphy
    Á¤»ó»ó(ïáßÈßÓ) Å©·Î¸¶Åä±×·¡ÇÇ
  • one-phase chromatography
    ÀÏ»ó(ìéßÓ) Å©·Î¸¶Åä±×·¡ÇÇ
  • partition phase
    ºÐ¹è»ó(ÝÂÛÕßÓ)
  • phase
    »ó(ßÓ)
  • phase contrast microscope
    À§»óÂ÷(êÈßÓó¬) Çö¹Ì°æ(ßÓÓßðÎúéÚ°Ìð)
  • phase partition
    »óºÐ¹è(ßÓÝÂÛÕ)
  • phase plate
    »óÆÇ(ßÓ÷ù)
  • phase rule
    »óÀ²(ßÓëÏ)
  • phase shift mutation
    »óÀ̵¿ º¯ÀÌ(ßÓì¹ÔÑܨì¶)
  • phase test
    »ó½ÃÇè(ßÓãËúÐ)
  • phase transfer
    »óÀüÀÌ(ßÓï®ì¹)
  • phase variation
    »óº¯µ¿(ßÓܨÔÑ)
  • preinductive phase
    ÀüÀ¯µµ±â(îñë¯ÓôÑ¢)
  • productive phase
    »ý»ê±â(ßæß§Ñ¢)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • out of phase
    Å»À§»óÀÇ
  • out of phase gradient echo image
    Å»À§»ó°æ»ç¿¡ÄÚ¿µ»ó
  • phase
    ȗ, ˤȗ
  • phase angle
    À§»ó°¢
  • phase artifact
    À§»óÀΰø¹°
  • phase axis
    ˤȗ̈
  • phase cancellation artifact
    À§»ó¸»¼Ò(»ó¼â)Àΰø¹°
  • phase coherence
    À§»ó°áÁý
  • phase conjugate symmetry
    À§»óȸº¹´ëĪ, À§»ó°ø¾×´ëĪ
  • phase contrast
    À§»ó´ëÁ¶
  • phase contrast MR angiography
    À§»ó´ëÁ¶ÀÚ±â°ø¸íÇ÷°üÁ¶¿µ¼ú
  • phase curve
    À§»ó°î¼±
  • phase display
    À§»óÇ¥½Ã
  • phase encode direction
    À§»óºÎȣȭ¹æÇâ
  • phase encoding
    À§»óºÎȣȭ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NCS National Collaborative Study; neocarcinostatin; nerve conduction study; newborn calf serum; no conce...
LPD Luteal Phase Defect
AP accessory pathway; accounts payable; acid phosphatase; acinar parenchyma; action potential; active p...
APP acute phase protein; alum-precipitated pyridine; aminopyrazolopyrimidine; amyloid peptide precursor;...
APR abdominoperineal resection; absolute proximal reabsorption; acute phase reaction or reactant; amebic...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
Study B study
Study I study
APRF 3/acute phase response factor
SPRIA Solid Phase Radioimmune Assay
APR Acute Phase Response
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • prospective study
    ÀüÇâÀû ¿¬±¸, ÃßÀû ¿¬±¸
  • psychophysical study
    Á¤½Å ½ÅüÇÐ ¿¬±¸
  • psychophysiological study
    Á¤½Å »ý¸®ÇÐÀû ¿¬±¸
  • radionuclei study
    ÇÙ ¹æ»ç¼± ÃÔ¿µ
  • real time study
    ½Ç½Ã°£ °Ë»ç
  • secretory study
    ºÐºñ °Ë»ç
  • study cast
    ¿¬±¸¿ë ¸ðÇü, Áø´Ü ¸ðÇü
    µ¿ÀǾî=diagnostic cast.
  • video-urodynamic study
    ºñµð¿À ¿ä¿ªÇÐ °Ë»ç
  • accelerated death phase
    °¡¼Ó »ç¸ê±â
  • acceleration phase
    ÃËÁø±â, °¡¼Ó±â
    ¹Ì»ý¹° ¹è¾ç ½Ã °©Àڱ⠼ºÀåÀÌ Áõ°¡ÇÏ´Â ½Ã±â.
  • acute phase protein
    ±Þ¼º±â ´Ü¹éÁú
    °¨¿°À̳ª Á¶Á÷ ¼Õ»óÀÌ ÀÖÀ» ¶§ Á¤»óº¸´Ù 2-100¹è Á¤µµ Áõ°¡ÇÏ´Â Ç÷Àå ´Ü¹éÁúÀ» ÃÑĪÇÏ¿© APP¶ó°í ÇÏ¸ç ¼±Ãµ¼º ¸é¿ª¿¡ °ü¿©ÇÑ´Ù.
  • acute phase reaction
    ±Þ¼º±â ¹ÝÀÀ
  • acute phase serum
    ±Þ¼º º´±â Ç÷û
  • anal-sadistic phase
    Ç×¹®-°¡Çбâ, Ç×¹®-°¡ÇÐ ½Ã±â
  • arousal phase
    ÀáÀ» ±ú´Â ½Ã±â
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
study, crossover A type of clinical trial in which the study subjects receive each treatment in a random order. In this type of study, every patient serves as his or her own control.
(12 Dec 1998)
study, cross-sectional A study done at one time, not over the course of time. A cross-sectional study a disease such as aids might be designed to learn its prevalence and distribution within the population at one point in time. Also known as a synchronic study.
(12 Dec 1998)
study, diachronic See: Study, longitudinal.
(12 Dec 1998)
study, longitudinal A study done over the passage of time. For example, a longitudinal study of children with down syndrome (trisomy 21) might involve the study of 100 children with this condition from birth to 10 years of age. Also called a diachronic study. The opposite of a cross-sectional (synchronic) study.
(12 Dec 1998)
study, preclinical A study to test a drug, procedure or medical treatment in animals. The aim is to collect data in support of safety. Preclinical studies are required before clinical trials can be started.
(12 Dec 1998)
study, synchronic See: Study, cross-sectional.
(12 Dec 1998)
synchronic study <epidemiology> A study in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with longitudinal studies which are followed over a period of time.
Synonym: horizontal study.
(18 Jul 2002)
diachronic study A study done over the course of time. For example, a longitudinal study of children with Down syndrome (trisomy 21) might involve the study of 100 children with this condition from birth to 10 years of age. Also called a longitudinal study. The opposite of a synchronic (cross-sectional) study.
(12 Dec 1998)
double-blind study A study in which neither the experimenter nor any other assessor of the results, including patients, know which group is subject to which procedure, thus helping assure that the biases or expectations of either will not influence the results.
(05 Mar 2000)
epidemiologic study characteristics Types and formulations of studies used in epidemiological and clinical research.
(12 Dec 1998)
twin study A method of detecting genetic causes in human traits and genetic factors in behaviour using sets of twins.
(12 Dec 1998)
foetal doppler study <radiology> Non-stress test (NST), external monitoring for 20 minutes; poor specificity, greater than4 foetal heart accelerations (greater than15 bpm over baseline for 15 seconds) following foetal movement in foetus greater than34 weeks, no heart accelerations in immaturity, sleep, maternal sedation contraction stress test (CST), external monitoring after oxytocin or maternal breast stimulation, greater than 3 uterine contraction in 10 minutes; 50% specificity uterine and umbilical artery waveform, elevated systolic:diastolic ratio = increased vascular resistance foetal aortic flow volume, 185-246 ml/kg/min see also: biophysical profile, intrauterine growth retardation (IUGR)
(12 Dec 1998)
follow-up study Study in which persons exposed to risk or given a designated preventive or therapeutic regimen are observed over a period or at intervals to determine the outcome of the exposure or regimen.
(05 Mar 2000)
Framingham Heart study <epidemiology> Ongoing epidemiologic study of a cohort of over 5,000 of the population of Framingham, MA conducted since 1949 under the auspices of the National Institutes of Health and Boston University.
(05 Mar 2000)
longitudinal study <epidemiology> A study taking place over time. If individuals are followed, this is a longitudinal cohort study. If individuals are not followed, but classes (usually age classes) are restudied, this is a longitudinal cross-sectional study.
The converse of a horizontal study.
(05 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • nature study
    ÀÚ¿¬°øºÎ(²É »õ ±¤¼® ³¯¾¾µîÀÇ °üÂû,±¹¹ÎÇб³ÀÇ Çаú ''
  • study
    ½ÀÀÛ;½ÃÀÛ;¼­Àç;¿¬±¸½Ç;¾Ö¾¸
  • study
    ÇÏ´Ù;¾Ö¾²´Ù;(¹Ì)¼÷°íÇÏ´Ù
  • study
    ÇÏ´Ù;(´ë»çµîÀ»)¾Ï±âÇÏ´Ù
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á